Hjem › B-celle lymfom › Texas › Houston
Kliniske studier for B-celle lymfom i Houston, TX
16 studier for B-celle lymfom søker deltakere på steder i og rundt Houston (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
RekruttererObservasjonsstudie
- Texas Children's Hospital, Houston
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
RekruttererFase 3
- Md Anderson Cancer Center, Houston
A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
RekruttererFase 2
- MD Anderson Cancer Center, Houston
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
RekruttererFase 1
- MD Anderson Cancer Center, Houston
A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL
RekruttererFase 2
- M D Anderson Cancer Center, Houston
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
RekruttererFase 2
- Research Site, Houston
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
RekruttererFase 1/2
- The University of Texas Md Anderson Cancer Center, Houston
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
RekruttererFase 1/2
- Research Site, Houston
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
RekruttererFase 1
- Clinical Trial Site, Houston
Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances
RekruttererFase 1/2
- M D Anderson Cancer Center, Houston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
RekruttererFase 3
- MD Anderson Cancer Center, Houston
A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas
RekruttererFase 1
- The University of Texas M D Anderson Cancer Center, Houston
DALY II USA/ MB-CART2019.1 for DLBCL
RekruttererFase 2
- The University of Texas MD Anderson Cancer Center, Houston
Phase 1 Trial of BTM-3566 in Relapsed/Refractory Mature B Cell Lymphomas
RekruttererFase 1
- MD Anderson Cancer Center, Houston
Trial of ONC-PluReceptor NK Cells With Epcoritamab and Tafasitamab for Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
RekruttererFase 1/2
- The University of Texas M. D. Anderson Cancer Center, Houston
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
RekruttererFase 1
- Texas Children's Hospital/Baylor College of Medicine, Houston
B-celle lymfom-studier i andre byer
- New York City, NY19 studier
- Chicago, IL12 studier
- Nashville, TN11 studier
- Philadelphia, PA11 studier
- Rochester, MN10 studier
- Baldwin Park, CA9 studier
- Milwaukee, WI9 studier
- Cleveland, OH9 studier
- Salt Lake City, UT8 studier
- Boston, MA8 studier
- Columbus, OH7 studier
- Pittsburgh, PA7 studier
Andre studier i Houston
- Ikke-småcellet lungekreft145 studier
- Brystkreft126 studier
- Kreft (alle typer)121 studier
- Metastatisk kreft104 studier
- Kolorektal kreft102 studier
- Eggstokkreft89 studier
- Akut myelogen leukemi85 studier
- Lungekreft78 studier
- Prostatakreft76 studier
- Endometriekreft68 studier
- Pankreaskreft61 studier
- Melanom59 studier
Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.